Skip to main content

Year: 2024

Teleradiology Market to Surpass USD 30 Billion by 2031 | SkyQuest Technology

Teleradiology Market size is poised to grow from USD 9.58 billion in 2023 to USD 30.13 billion by 2031, growing at a CAGR of 15.40% during the forecast period (2024-2031). Westford, USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — Global Teleradiology Market size to grow from USD 9.58 billion in 2023 to USD 30.13 billion by 2031, growing at a CAGR of 15.40% during the forecast period (2024-2031). In recent times, the Teleradiology Market is witnessing as surge due to the increasing prevalence of target diseases and growing demand for teleradiology to get second opinions during emergencies. Furthermore, the incidence of COVID-19 has also emphasized on the significance of teleradiology. The lack of medialprofessionals, particularly in the sub-specialist segment, like paediatric, neurology, and musculoskeletal radiology are resulting in the...

Continue reading

Hudbay Delivers Strong Third Quarter 2024 Results with Record Gold Production in Manitoba; 2024 Production Guidance Reaffirmed and Cost Guidance Further Improved

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “company”) (TSX, NYSE: HBM) today released its third quarter 2024 financial results. All amounts are in U.S. dollars, unless otherwise noted. All production and cost amounts reflect the Copper Mountain mine on a 100% basis, with Hudbay owning a 75% interest in the mine. “Our enhanced operating platform delivered strong operating and financial results with record gold production in Manitoba and robust cost control across the business leading to expanded margins,” said Peter Kukielski, President and Chief Executive Officer. “The third quarter demonstrated Hudbay’s unique copper and gold diversification, providing attractive free cash flow generation and strong leverage to higher metal prices. New quarterly record throughput levels were achieved at the...

Continue reading

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced financial results for the third quarter and nine months ended September 30, 2024, and provided a business update. “Our team has made great progress over the last several months...

Continue reading

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company’s management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton New York Times Square Hotel, New York City About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval...

Continue reading

Karolinska Development’s Extraordinary General Meeting 2024

STOCKHOLM, SWEDEN – November 13, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held an Extraordinary General Meeting on November 13, 2024, at which the shareholders resolved as follows. Resolution on election of a new member of the Board of Directors: It was resolved, in accordance with the proposal from the company’s largest shareholder, invoX Pharma Ltd., to elect Will Zeng as a new director with director Theresa Tse resigning from her position at the Extraordinary General Meeting. Determination of fee to the new member of the Board of Directors: It was noted that the Annual General Meeting on May 16, 2024, resolved that the Board of Directors, except for the chairperson, would be paid a fixed amount of SEK 200,000 to be paid out in proportion to board meetings attended. It was resolved, in accordance...

Continue reading

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway; submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming expected milestones. Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals commented: “Earlier today, we announced results...

Continue reading

Enlight Renewable Energy Reports Third Quarter 2024 Financial Results

All of the amounts disclosed in this press release are in U.S. dollars unless otherwise noted TEL AVIV, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) — Enlight Renewable Energy Ltd. (NASDAQ: ENLT, TASE: ENLT) today reported financial results for the third quarter ending September 30, 2024. The Company’s earnings conference call and webcast will be held today at 8:00 AM ET. Registration links to both the call and the webcast can be found at the end of this earnings release.  The entire suite of the Company’s 3Q24 financial results can be found on our IR website at https://enlightenergy.co.il/data/financial-reports/       Financial Highlights 9 months ending September 30, 2024Revenue of $285m, up 56% year over year Adjusted EBITDA1 of $214m, up 50% year over year Net income of $58m, down 29% year over year Cash flow from operations...

Continue reading

IREN to Release Q1 FY25 Results on November 26, 2024

SYDNEY, Nov. 13, 2024 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: IREN) (together with its subsidiaries, “IREN”) today announced that it will release its financial results for the three months ended September 30, 2024, on Tuesday, November 26, 2024 and host a conference call beginning at 5:00 p.m. New York time. The webcast will be recorded, and the replay will be accessible shortly after the event at https://iren.com/investor/events-and-presentationsWebcast and Conference Call DetailsTime & Date: 5:00 p.m. New York time, Tuesday, November 26, 2024    9:00 a.m. Sydney time, Wednesday, November 27, 2024    Participant Registration Link    Live Webcast Use this link    Phone Dial-In with Live Q&A Use this link         Participants joining the conference call via the phone dial-in...

Continue reading

MT Højgaard Holding A/S: MT Højgaard Danmark wins refurbishment of social housing in Ballerup

MT Højgaard Holding’s business unit MT Højgaard Danmark will refurbish 456 family housing units in social housing area Grantofteparken for organisations DAB and Ballerup almennyttige Boligselskab. MT Højgaard Danmark has been selected as general contractor for the refurbishment assignment with a contract value of DKK 211 million. The residential units are two-storey row houses, which will be fitted with new bathrooms, windows and perimeter drains as well as improved ventilation. The refurbishment work commences on 1 January 2025 with planned delivery on 1 January 2027. “We see a lot of interesting refurbishment projects to bid on in the coming years. Grantofteparken is a large refurbishment project with many repetitions, and we will bring all of our experience to good use over the 24-month period to deliver a good result for the developer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.